ASCO 2022 | Expanded efficacy and safety analyses from CheckMate 648

First-line chemotherapy for advanced esophageal squamous cell carcinoma (ESCC) results in poor outcomes, In this interview, Ian Chau, MD, FRCP, The Royal Marsden NHS Foundation, London, UK, discusses findings from CheckMate 648 (NCT03143153), an open-label Phase III study evaluating nivolumab plus chemotherapy or ipilimumab versus chemotherapy as first-line treatment for advanced ESCC, which previously reported overall survival benefit for both nivolumab + chemotherapy and nivolumab + ipilimumab. In this expanded report with 13-month minimum follow up, nivolumab + chemotherapy and nivolumab + ipilimumab demonstrated favorable PFS2 and a higher proportion of patients with prolonged duration of response vs chemotherapy alone, as well as acceptable safety profiles. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.